

neurotoxin of the same type and from the same species, wherein said light chain is inactivated by at least one said amino acid mutation, and

- G
G
G
G
- ii) an unaltered Clostridial neurotoxin heavy chain which has binding specificity for a target nerve cell; and
 - b) a drug or other bioactive molecule joined to the inactivated light chain of said inactive neurotoxin,
wherein said inactive neurotoxin is internalizable by said target nerve cell.

~~36.~~ (Twice Amended) A pharmaceutical composition for treatment of a neuromuscular dysfunction in a mammal, comprising:

- Q2
- a) an inactive Clostridial neurotoxin comprising
 - i) a[n inactivated] light chain containing one or more amino acid sequence mutation as compared to the amino acid sequence of the light chain of a wild-type Clostridial neurotoxin of the same type and from the same species, wherein said light chain is inactivated by at least one said amino acid mutation, and
 - ii) an unaltered Clostridial neurotoxin heavy chain which has binding specificity for a target nerve cell; and
 - b) a drug or other bioactive molecule joined to the inactivated light chain of said inactive neurotoxin,
wherein said inactive neurotoxin is internalizable by said target nerve cell, and a pharmaceutically acceptable excipient.

10
~~42.~~ (Twice Amended) A method for treating a mammal having acute botulinum poisoning, comprising:

- 3
- introducing into said mammal an effective quantity of a pharmaceutically active solution comprising
 - a) an inactive Clostridial neurotoxin comprising
 - i) a[n inactivated] light chain containing one or more amino acid sequence mutation as compared to the amino acid sequence of the light chain of a wild-type Clostridial neurotoxin of the same type and from the same species, wherein said light chain is inactivated by at least one said amino acid mutation, and